--- - |2 Abstract We would like to thank Bharadwaj et al. for their 2017 publication which provides robust evidence that subacute pyridostigmine administration heightens heart rate recovery (HRR) by augmenting cholinergic stimulus to the heart, thereby increasing parasympathetic tonus in heart failure (HF).1 Findings on HRR in the human population, which were published by another group in 20162 and correlate diminished HRR with HF mortality, belie what we truly know concerning the nebulous role that parasympathetic activation plays relative to standard therapy in HF. Specifically, we can conclude from Bharadwaj et al. that impaired HRR lessens parasympathetic activity, which opens up questions regarding improving parasympathetic tonus in HF1, which could in turn shed light on the morbidity and mortality seen in this population. This article is protected by copyright. All rights reserved. - Clinical and Experimental Pharmacology and Physiology, Volume 0, Issue ja, -Not available-.